| zhong, haijun |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
ASTRUM-015, NCT04547166: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) |
|
|
| Recruiting | 2/3 | 568 | Japan, RoW | HLX10, serplulimab, HLX04、, Bevacizumab | Shanghai Henlius Biotech | Metastatic Colorectal Cancer | 09/25 | 12/26 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Lv, Wangxia |
NCT04415385: The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma |
|
|
| Recruiting | 2 | 48 | RoW | Camrelizumab, SHR-1210, Apatinib, Apatinib Mesylate | Zhejiang Cancer Hospital | Pancreatic Cancer | 06/22 | 06/23 | | |
NCT05963087: Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 22 | RoW | Cetuximab Dabrafenib Tislelizumab | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 02/25 | 06/26 | | |
NCT06195670: Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC |
|
|
| Not yet recruiting | 1/2 | 220 | RoW | Experimental, SCRT + fruquintinib + sintilimab, Active Comparator, Bevacizumab + Capecitabine | Zhejiang Cancer Hospital | CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma | 01/26 | 01/27 | | |
NCT06379399: Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC |
|
|
| Recruiting | 1/2 | 26 | RoW | Cetuximab, Erbitux, Trifluridine/Tipiracil, TAS-102, FTP/TPI | Wangxia LV | Colorectal Cancer Metastatic | 03/25 | 12/25 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Feng, Tingting |
NCT04946682: Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment |
|
|
| Recruiting | N/A | 484 | RoW | Types of etiological diagnostic methods | Wen-hong Zhang | Encephalitis, Meningitis, Meningoencephalitis, Next-Generation Sequencing, Polymerase Chain Reaction | 04/22 | 04/23 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Zhong, Haiyun |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Yuan, Meiqin |
NCT05963087: Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 22 | RoW | Cetuximab Dabrafenib Tislelizumab | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 02/25 | 06/26 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Liu, Bixia |
NCT05963087: Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 22 | RoW | Cetuximab Dabrafenib Tislelizumab | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 02/25 | 06/26 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Shi, Zhong |
NCT05963087: Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 22 | RoW | Cetuximab Dabrafenib Tislelizumab | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 02/25 | 06/26 | | |
NCT06195670: Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC |
|
|
| Not yet recruiting | 1/2 | 220 | RoW | Experimental, SCRT + fruquintinib + sintilimab, Active Comparator, Bevacizumab + Capecitabine | Zhejiang Cancer Hospital | CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma | 01/26 | 01/27 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Cheng, Chijun |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Cheng, Junchi |
NCT05963087: Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 22 | RoW | Cetuximab Dabrafenib Tislelizumab | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 02/25 | 06/26 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
| Zhong, Hanjun |
NCT05963087: Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 22 | RoW | Cetuximab Dabrafenib Tislelizumab | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 02/25 | 06/26 | | |
| Zhao, Yazhen |
NCT05963087: Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 22 | RoW | Cetuximab Dabrafenib Tislelizumab | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 02/25 | 06/26 | | |
